UPTRAVI (selexipag) Pediatric pulmonary arterial hypertension. Phase III US. Phase III EU. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer ...
Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* (2019-2023 Key Filings, As Outlined at 2019 Pharm Business Review) Selective Highlights as of January 26, 2021 *Filings/approvals assumed to be in the US and EU unless otherwise noted.
Johnson & Johnson has an expansive archive of existing drug compounds—and two researchers are leading the charge in combing through this molecular storehouse in pursuit of a possible breakthrough. It's the sixth leading cause of death in the United States, with no existing cure.
04.11.2021 · In addition to U.S. Breakthrough Therapy Designation (BTD) granted in December 2019, by the U.S. FDA, Janssen also received Orphan Drug Designation for cilta-cel, in February 2019. In December 2020, Janssen announced initiation of a rolling submission of its BLA to the U.S. FDA for cilta-cel, which was accepted under Priority Review in May 2021.
Nov 04, 2021 · In December 2020, Janssen announced initiation of a rolling submission of its BLA to the U.S. FDA for cilta-cel, which was accepted under Priority Review in May 2021. In November 2021, Janssen announced the extension of the PDUFA date.
Sep 14, 2020 · The Janssen Pharmaceutical Companies of Johnson & Johnson today announced multiple data presentations from its oncology portfolio and pipeline, in ... 2020. 15 Johnson & Johnson. Janssen Announces ...
Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* Selective Highlights as of April 14, 2020 NME PLANNED FILINGS 2020-2023* ERLEADA® (apalutamide) (EU) Non-metastatic prostate cancer Adjunctive treatment for major depressive disorder with insomnia symptoms
Select New Molecular Entity programs recently approved or with potential filings in the US/EU within a specified window as outlined in the Pharmaceutical ...
Late Stage Development. June 23, 2021. Select programs in the pivotal phase and in registration/approval for the US/EU (removed after programs achieve approval in both US/EU).
Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* Selective Highlights as of October 13, 2020. NME PLANNED FILINGS 2020-2023*
May 29, 2020 · RARITAN, N.J., May 29, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the latest research from its innovative oncology portfolio and pipeline of ...
Explore Janssen's innovative medical research & pharmaceutical product development practices to see how Janssen is creating a future where disease is a ...
Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* (2019-2023 Key Filings, As Outlined at 2019 Pharm Business Review) Selective Highlights as of January 26, 2021 *Filings/approvals assumed to be in the US and EU unless otherwise noted.
Janssen Pharmaceutical Companies of Johnson & Johnson Selected NME Pharmaceutical Pipeline - Recent Approvals/Potential Filings* Selective Highlights as of October 13, 2020
Mechanism: PD-1/CTLA-4 bispecific mAb + VEGF; Area under investigation:advanced renal cell carcinoma; Date commenced phase: Q3 2020; Estimated Filing ...
14.09.2020 · beerse, belgium-- ( business wire )--the janssen pharmaceutical companies of johnson & johnson today announced multiple data presentations from its oncology portfolio and pipeline, including key...
Late Stage Development. June 23, 2021. Select programs in the pivotal phase and in registration/approval for the US/EU (removed after programs achieve approval in both US/EU).